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Excimer laser coronary atherectomy (ELCA) uses a xenon-chloride excimer laser to produce bursts of ultraviolet light at 308 nm with pulse frequency of 
25-80 Hz and fluence of 30-80 mJ/mm2.1 ELCA was ini-
tially approved by the United States Food and Drug Admin-
istration for percutaneous coronary intervention (PCI) in 
1992 for multiple indications, including occluded saphenous 
vein bypass graft (SVG), ostial lesions, long lesions (>20 mm 
in length), moderately calcified lesions, eccentric lesions, 
chronic total occlusions (CTOs) crossable with a guidewire, 
balloon refractory lesions, and in-stent restenosis (ISR).2 In 
recent years, laser use has increased concomitantly with the 
performance of increasingly complex PCIs.3 However, few 
contemporary data exist on the real-world procedural indi-
cations and outcomes of ELCA. We therefore developed a 
multicenter registry to examine the contemporary indica-
tions and outcomes of ELCA-assisted PCI.
Methods
Patient population. We analyzed baseline clinical and 
angiographic characteristics and outcomes of 130 target le-
sions in 121 consecutive laser-assisted PCIs performed in 
116 patients between 2008 and 2016 at three United States 
Department of Veterans Affairs (VA) medical centers.
Enrollment was performed only during part of the study 
period at some centers due to participation in other stud-
ies. Consecutive patients who were undergoing laser-assisted 
PCI at each participating VA center were identified via the 
clinical database of the cardiac catheterization laboratories. 
Data collection was performed both prospectively and ret-
rospectively and was recorded in a dedicated online data-
base (LAVA: Laser VA Registry) (Clinicaltrials.gov identifier: 
NCT02789462). Informed consent was waived for the ret-
rospective component of the study, but was obtained from 
patients enrolled prospectively. The study was approved by 
the Institutional Review Board of each site. 
Study investigation sites, electronic data capture system 
description, and study definitions are listed in Supplemental 
Appendix S1 (available at www.invasivecardiology.com).
Statistical analysis. Continuous variables were present-
ed as mean ± standard deviation or median (interquartile 
range [IQR]). Categorical data were reported as frequencies 
or percentages. All statistical analyses were performed with 
JMP 11.0 (SAS Institute). 
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Results
During the study period, a total of 116 patients under-
went 121 laser-assisted PCIs at the three participating cen-
ters. The baseline clinical characteristics of the study patients 
are shown in Table 1. Mean age was 68.5 ± 9 years and 97% of 
the patients were men. Patients had high prevalence of diabe-
tes mellitus (63%), prior coronary artery bypass graft (CABG) 
surgery (41%), and prior myocardial infarction (MI) (60%). 
The angiographic characteristics of the study population 
are summarized in Table 2. During the study period, a total 
of 130 lesions were treated with ELCA. The most common 
target vessel was the left anterior descending artery (32%), 
followed by the right coronary artery (30%), circumflex 
(20%), SVG (12%), and left main artery (0.05%). Moderate 
to severe calcification and moderate to severe proximal ves-
sel tortuosity were present in 62% and 24%, respectively. The 
target lesions were highly complex; 28% involved a bifurca-
tion and 37% were due to in-stent restenosis. Intravascular 
ultrasound was used in 50% and optical coherence tomogra-
phy in 11% of target lesions.
The most common indication for ELCA was balloon-un-
crossable lesions (43.8%), followed by balloon-undilatable 
lesions (40.8%) and thrombotic lesions (12.3%). Other in-
dications for laser included treatment of a complication 
(wire entrapment) and SVG lesions (Figure 1). Most lesions 
(91.4%) were treated with 0.9 mm laser catheters, 73.3% 
with rapid-exchange catheters, and 18.1% with over-the-
wire catheters. The mean number of laser runs was 4.48 ± 
2.9 per lesion, with 40 sec (IQR, 28-64 sec) lasing time.
The procedural outcomes are shown in Table 3 and Figure 
1. Use of laser was associated with high technical success rate 
Table 1. Baseline clinical characteristics of the study patients.
Variable Overall (n = 116)
Age (years) 68.5 ± 9
Men 97%





Left ventricular ejection fraction (%) 48.8 ± 15.4
Family history of coronary artery disease 30%
Congestive heart failure 37%
Prior myocardial infarction 60%
Prior coronary artery bypass grafting 41%
Prior cerebrovascular disease 16%
Prior peripheral vascular disease 17%
Baseline creatinine (mg/dL) 1.1 (0.9-1.3)
Data provided as mean ± standard deviation, percentage, or median 
(interquartile range).
Table 2. Procedural strategy, angiographic characteristics, and 
laser-assisted PCI techniques of the study lesions.
Variable Overall (n = 130)
Angiographic characteristics
Target vessel
   Right coronary artery 30.0%
   Left coronary artery 32.0%
   Left circumflex artery 20.0%
   Left main coronary artery 0.05%





Vessel diameter (mm) 3.0 (2.5-3.5)
Lesion length (mm) 22 (15-44)
Procedural strategy
Intravascular ultrasound 50.0%










   Balloon-uncrossable lesion 43.8%
   Balloon-undilatable lesion 40.8%
   Thrombus 12.3%
   Other* 3.1%
Number of stents used 1.95 ± 1.5
Laser-assisted PCI techniques
Laser type
   1.7 mm rapid-exchange catheter 1.7%
   1.4 mm  rapid-exchange catheter 6.9%
   0.9 mm  rapid-exchange catheter 73.3%
   0.9 mm over-the-wire catheter 18.1%
Starting fluence (mJ/mm2) 60 (42.5-80)
Maximum fluence (mJ/mm2) 80 (60-80)
Starting frequency (Hz) 60 (40-80)
Maximum frequency (Hz) 80 (40-80)
Number of lasing passes (n) 4.48 ± 2.9
Total lasing time (sec) 40 (28-64)
Data provided as mean ± standard deviation, percentage, or median 
(interquartile range). *Other indications for laser included complica-




















Vol. 30, No. 6, JuNe 2018 197
Contemporary Laser Use DUring pCi KaraCsonyi, et aL.
(90.0%), procedural success rate (88.8%), and laser success rate 
(84.4%). Overall, the MACE rate was low (3.45%). However, 
in patients with thrombotic lesions, the MACE rate was 6.25%. 
Two patients died after the laser procedure. One of them de-
veloped acute ST-segment elevation after the procedure, but 
the study lesion in which laser was used was found to be 
patent and a different lesion was stented; however, the patient 
developed pulseless electrical activity overnight and died. The 
other patient died 2 days after an unsuccessful procedure due 
to cardiogenic shock. There was no stroke, emergency CABG, 
or pericardiocentesis. Perforation occurred in 2 lesions, both 
of which were severely calcified. Both perforations were Ellis 
class 2, occurred after stenting, and resolved after prolonged 
balloon inflation, without requiring pericardiocentesis.
Median procedure time was 120 min (IQR, 81-191 min), 
median fluoroscopy time was 32 min (IQR, 20-57 min), 
median air kerma radiation dose was 2.76 Gy (IQR, 1.32-
5.01 Gy), and median contrast volume was 273 mL (IQR, 
201-362 mL). 
Discussion
The main findings of our study are that ELCA was used 
in highly complex lesions (mainly balloon-uncrossable and 
balloon-undilatable lesions), and was associated with high 
technical success rate (90.0%) and procedural success rate 
(88.8%), and low MACE rate (3.45%). 
Early studies compared ELCA with balloon angioplasty. The 
AMRO (AMsterdam-ROtterdam) trial did not show superi-
ority of laser over balloon angioplasty for long-term clinical 
and angiographic outcomes after treatment of coronary occlu-
sions.4 The ERBAC (Excimer laser, Rotational atherectomy, 
and Balloon Angioplasty Comparison) study resulted in better 
procedural success with rotational atherectomy (RA), but the 
incidence of restenosis was equally high with atherectomy tech-
niques.5 These studies used an old laser catheter type without 
saline infusion, and stenting was not used in all cases. After the 
introduction of drug-eluting stents, use of ELCA decreased until 
recently. Fernandez et al used ELCA in 0.84% of balloon failure 
PCI cases over a 4-year period, with nearly one-third of these 
cases being CTOs.6 In a single-center study of CTO-PCI, Patel 
et al reported ELCA use in 8.4% of balloon-uncrossable lesions.7
As reflected in our study, ELCA use has increased in recent 
years as a result of the growth of complex PCI, such as PCI of 
CTOs and calcified and thrombotic lesions. The most com-
mon use of laser was for balloon-uncrossable lesions (43.8%) 
(Figure 2; Supplemental Appendix S1). Balloon-uncrossable 
lesions cannot be crossed with a balloon after successful guide-
wire crossing.7 Use of ELCA for such lesions in our study was 
Table 3. Procedural outcomes of the study patients, classified according to the laser indication.
Variable Overall Balloon Uncrossable Balloon Undilatable Thrombus Other*
Technical success 90.0% 87.8% 94.3% 81.3% 100%
Procedural success 88.8% 83.7% 93.8% 87.5% 100%
Laser success 84.4% 74.5% 94.3% 81.3% 100%
Procedural time (min) 120 (81-191) 128 (70-224) 120 (90-162) 99 (52-173) 69 (62-163)
Fluoroscopy time (min) 32 (20-57) 40 (19-76) 30 (23-41) 25 (17-41) 13 (9-51)
Air kerma radiation dose (Gy) 2.76 (1.32-5.01) 3.44 (1.51-5.92) 2.81 (1.34-5.03) 2.30 (1.32-2.90) 1.49 (0.66-5.19)
Contrast volume 273 (201-362) 274 (188-382) 290 (225-361) 285 (213-369) 149 (87-225)
LV assist device used 9.6% 10.4% 10.4% 0.0% 25.0%
Major adverse cardiac events 3.45% 4.08% 2.08% 6.25% 0.0%
Death 1.72% 2.04% 0.0% 6.25% 0.0%
Acute Q-wave MI 0.0% 0.0% 0.0% 0.0% 0.0%
Acute myocardial infarction 0.86% 2.04% 0.0% 0.0% 0.0%
Re-PCI 2.59% 4.08% 2.08% 0.0% 0.0%
Stroke 0.0% 0.0% 0.0% 0.0% 0.0%
Emergency CABG 0.0% 0.0% 0.0% 0.0% 0.0%
Equipment loss 0.86% 0.0% 0.0% 0.0% 25.0%
Perforation 1.72% 4.08% 0.0% 0.0% 0.0%
Vascular access complication 0.86% 0.0% 2.08% 0.0% 0.0%
Dissection/thrombus 4.31% 2.04% 8.33% 0.0% 0.0%
Pericardiocentesis 0.0% 0.0% 0.0% 0.0% 0.0%
Data provided as percentage or median (interquartile range).
LV = left ventricular; PCI = percutaneous coronary intervention; CABG = coronary artery bypass grafting.
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associated with 87.8% technical success, 74.5% laser success, and 
83.7% procedural success rates. Laser is a powerful option for 
treating balloon-uncrossable lesions since it can be used over 
any standard 0.014˝ guidewire, in contrast to rotational and or-
bital atherectomy, which require insertion of specialized guide-
wires.8 Shen et al reported using ELCA in 33 patients, of whom 
21 had balloon-uncrossable lesions, with success achieved in 19 
patients (90%) and no complications related to laser use.9 In 
a contemporary multicenter CTO-PCI registry (PROGRESS 
CTO: Prospective Global Registry for the Study of Chron-
ic Total Occlusion Intervention10) 9% of all attempted CTOs 
were balloon uncrossable; ELCA was used in 18% of these cases 
with high technical and procedural success rates (both 95%) and 
no associated complications.11
Fernandez et al used ELCA in 36 balloon-uncrossable 
lesions, of which 20 were lesions with TIMI 3 flow and 16 
were in the setting of a CTO. Among CTO lesions, proce-
dural success was achieved in 13 cases (81%) with laser alone. 
One case required combined ELCA and RA: laser was used 
first to allow passage of the RotaWire (Boston Scientific 
Corporation), which allowed RA and successful completion 
of the procedure (the “RASER” technique). In lesions with 
TIMI 3 flow (20 cases), ELCA alone led to procedural suc-
cess in 10 cases and ELCA combined with RA led to proce-
dural success in 7 cases, with 85% overall procedural success.6 
The second-most common indication for ELCA in our 
study was balloon-undilatable lesions (40.8%), which are le-
sions that cannot be expanded after high-pressure balloon in-
flations. In our study, such lesions were associated with the 
highest technical success rate (94.3%) and procedural success 
rate (93.8%). Fernandez et al reported use of ELCA in 22 pa-
tients with balloon-undilatable lesions, 2 (9%) of whom were 
in the setting of CTO-PCI (these 2 cases were successfully 
treated with ELCA alone). Of the remaining 20 cases with 
baseline TIMI 3 flow, a total of 18 were treated successfully 
with laser alone, 1 was treated successfully with laser com-
bined with RA, and 1 was treated successfully with RA alone.6 
In the LEONARDO (early outcome of high energy La-
ser [Excimer]-facilitated coronary angioplasty ON hARD and 
complex calcified and ballOon-resistant coronary lesions) reg-
istry, which enrolled 80 patients, ELCA was successful in 30 
of 32 balloon failure cases (93.7%) without any major com-
plications.12 Another registry examining balloon-undilatable 
lesions, the ELLEMENT (Excimer Laser LEsion Modifica-
tion to Expand Non-dilatable sTents) registry, reported suc-
cess after laser-assisted stent dilation in 27 of 28 cases (96.4%). 
Periprocedural MI occurred in 7.1%, transient slow-flow in 
3.6%, and transient ST-segment elevation in 3.6% of the pa-
tients.13 In some patients, contrast-enhanced laser therapy was 
used to modify balloon-undilatable lesions.13-15 The recently 
 A
 B  C
FIGURE 1. Procedural characteristics of laser-assisted percutaneous coronary intervention (PCI). (A) Technical and procedural out-
comes of study patients overall and according to indication for use of laser. (B) Indications for use of laser during PCI in contemporary 
practice. (C) Types of laser catheters used in the present study. MACE = major adverse cardiac events; Rx = rapid-exchange excimer 
laser catheter; OTW = over-the-wire excimer laser catheter. Other indications for laser included complications (guidewire entrapment) 
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published DERIST (combined 
use of Drug-eluting balloon and 
Excimer laser for coronary ar-
tery Restenosis In-Stent Treat-
ment) study enrolled 80 patients 
with ISR treated with laser and 
drug-coated balloons. This study 
showed clinical and angiographic 
long-term success in 91% of the 
patients without any postproce-
dural complications.16 While this 
technique of combining laser 
atherectomy with contrast in-
jection may be associated with 
a higher risk of perforation, it is 
one of the only interventional 
options to successfully dilate an 
under-expanded stent.
ISR can be challenging to 
treat, especially when it is due 
to stent under-expansion. The 
safety and efficacy of laser was 
shown to be equal to balloon 
angioplasty in 146 patients 
with ISR, despite higher lesion 
complexity in the multicenter 
LARS (Laser Angioplasty for 
Restenotic Stents) registry.17
Thrombus was the indication 
for ELCA in 12.3% of our study 
lesions (Figure 3; Supplemen-
tal Appendix S1). As expected 
given the acute presentation, 
thrombotic lesions were asso-
ciated with the lowest techni-
cal and procedural success rates 
(81.3% and 87.5%, respective-
ly), and the highest MACE rate 
(6.25%). Laser atherectomy in 
acute MI has several advantag-
es, such as rapid removal of the 
thrombus with vaporization of 
procoagulant reactants, reduc-
tion of the risk of distal embo-
lization, and debulking of un-
derlying plaque.18 Furthermore, 
the interaction of laser with 
platelets can result in “stunned 
platelets” – ie, decreased platelet 
aggregation and reduced platelet 
force development.19 Only one 
small, prospective, randomized 
trial with 27 patients evaluat-
ed laser angioplasty compared 
FIGURE 2. Use of laser in a balloon-uncrossable chronic total occlusion. (A) A 66-year-old 
man with medically refractory angina was referred for percutaneous coronary interven-
tion of a right coronary artery chronic total occlusion. (B) A retrograde crossing attempt 
via an occluded saphenous vein graft failed; the wire was exchanged later to a Pilot 200 
but could not make progress. (C, D, E) Antegrade crossing attempts with a Fielder FC 
guidewire resulted in successful lesion crossing. (F) The lesion could not be crossed even 
with small balloons (1.5 x 20 mm). (G) Laser atherectomy was performed with a 0.9 mm 
laser catheter at 60 mJ/mm2 fluency and 40 Hz frequency without any complications. 
(H) The lesion could then be crossed with balloons and predilated. (I, J) A 2.25 x 32 mm 
drug-eluting stent was deployed distally and a 2.5 x 38 mm drug-eluting stent was de-
ployed in the mid part of the vessel. (K) Optical coherence tomography showed well-ap-
posed stents with no dissection. (L) Final angiography showed well-expanded stents with 
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with conventional treatment 
in MI. The Laser-AMI (Laser 
angioplasty in Acute Myocar-
dial Infarction) study showed 
no difference in the main 
procedural outcomes be-
tween the groups, although 
the improvement in correct-
ed TIMI frame count was 
higher in the laser group.20 
The ULTRAMAN (Utility 
of Laser for TRanscatheter 
Atherectomy — Multicenter 
Analysis around Naniwa) reg-
istry evaluated success rate, 
TIMI flow, blush score, and 
complications between the 
rich-thrombus group (acute 
coronary syndrome and SVG) 
vs the poor-thrombus group 
(ISR, CTO, calcification, and 
long or bifurcation lesions) 
in 328 patients. Both groups 
were associated with high 
technical success rates (94.5% 
vs 97.3%; P=.28), but the 
TIMI flow grade and blush 
score were significantly low-
er and the complications rate 
was significantly higher in the 
rich-thrombus group.18 The 
CARMEL (Cohort of Acute 
Revascularization in Myo-
cardial Infarction with Exci-
mer Laser) registry examined 
outcomes of 151 acute MI 
patients (54% Q-wave and 
46% non-Q wave), several of 
whom had high-risk charac-
teristics, such as cardiogenic 
shock (13%) and SVG as the 
target lesion (21%). The study 
reported laser success in 95% 
and overall procedural success 
in 91%, with relatively low 
complication rates (death, 4%; 
dissection, 5%; perforation, 
0.6%; distal vessel occlusion, 
0.6%; and distal embolization, 
2%). Maximal laser gain was 
achieved in the lesions with 
extensive thrombus burden.21
Other indications for laser 
included complications (such 
FIGURE 3. Use of laser for treating a thrombotic lesion. (A) A 60-year-old man with multi-
ple prior percutaneous coronary interventions presented with non-ST elevation myocar-
dial infarction. Coronary angiography revealed an occluded left anterior descending cor-
onary artery (LAD). (B)  Angiography of the right coronary artery (RCA) revealed filling of 
the LAD from the RCA through septal collaterals. Bilateral femoral access was obtained. 
(C) The LAD in-stent restenotic lesion was crossed with a Pilot 200 wire; contralateral in-
jections verified the wire to be in the distal true lumen. (D) Thrombectomy was done with 
a 7 Fr Export catheter. (E) Laser atherectomy was performed with a 0.9 mm laser catheter 
at 60 mJ/mm2 fluency and 40 Hz frequency, restoring antegrade flow. (F, G, H) The lesion 
was predilated and stented with drug-eluting stents. (I) The in-stent restenosis in the cir-
cumflex was then treated with a 2.75 x 28 mm drug-eluting stent. (K) A filling defect was 
noted in the LAD stents, and was treated with balloon dilation and intravenous tirofiban. 
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as guidewire entrapment) and SVG lesions. SVG lesions can be 
challenging to treat because of the high rates of distal emboliza-
tion and ISR.22 Laser atherectomy can be useful in the treatment 
of these lesions because its 308 nm wavelength is absorbed by 
both atherosclerotic plaque and thrombus, potentially reducing 
the risk for distal embolization and the resultant periprocedural 
MI.23 Another potential utilization of ELCA is the treatment of 
CTOs, which often require managing various challenges such 
as an “impenetrable proximal cap.”24 In addition to this, ELCA 
could assist freeing the guidewire in case of entrapment; Kado-
hira et al reported a case where ELCA was used to free a guide-
wire that was entrapped between a newly deployed coronary 
stent and severely calcified vessel wall.25
Study limitations. First, LAVA is an observational reg-
istry without adjudication of clinical events by an indepen-
dent events committee. Second, core laboratory analysis was 
not performed, and therefore, assessment of angiograph-
ic characteristics was susceptible to operator-related bias. 
Third, procedures were performed by operators experienced 
in ELCA-assisted PCI, limiting extrapolation of the study 
results to less experienced centers and operators. Fourth, all 
study sites were VA hospitals, treating a primarily male pop-
ulation with multiple comorbidities.
Conclusion
In a contemporary multicenter United States registry, 
ELCA was commonly used in highly complex lesions and 
was associated with high technical and procedural success 
rates and low incidence of MACE. ELCA is a valuable tool 
in contemporary complex PCI practice. 
References
1. Topaz O, ed. Lasers in Cardiovascular Interventions. Springer; 2015.
2. Badr S, Ben-Dor I, Dvir D, et al. The state of the excimer laser for coro-
nary intervention in the drug-eluting stent era. Cardiovasc Revasc Med. 
2013;14:93-98.
3. Kirtane AJ, Doshi D, Leon MB, et al. Treatment of higher-risk patients with 
an indication for revascularization: evolution within the field of contem-
porary percutaneous coronary intervention. Circulation. 2016;134:422-
431.
4. Appelman YE, Koolen JJ, Piek JJ, et al. Excimer laser angioplasty versus 
balloon angioplasty in functional and total coronary occlusions. Am J 
Cardiol. 1996;78:757-762.
5. Reifart N, Vandormael M, Krajcar M, et al. Randomized comparison of 
angioplasty of complex coronary lesions at a single center. Excimer la-
ser, rotational atherectomy, and balloon angioplasty comparison (ER-
BAC) study. Circulation. 1997;96:91-98.
6. Fernandez JP, Hobson AR, McKenzie D, et al. Beyond the balloon: ex-
cimer coronary laser atherectomy used alone or in combination with 
rotational atherectomy in the treatment of chronic total occlusions, 
non-crossable and non-expansible coronary lesions. EuroIntervention. 
2013;9:243-250.
7. Patel SM, Pokala NR, Menon RV, et al. Prevalence and treatment of “bal-
loon-uncrossable” coronary chronic total occlusions. J Invasive Cardiol. 
2015;27:78-84.
8. Shammas N, ed. Textbook of Atherectomy. HMP Communications; 2016.
9. Shen ZJ, Garcia-Garcia HM, Schultz C, van der Ent M, Serruys PW. 
Crossing of a calcified “balloon uncrossable” coronary chronic to-
tal occlusion facilitated by a laser catheter: a case report and re-
view recent four years’ experience at the Thoraxcenter. Int J Cardiol. 
2010;145:251-254.
10. Christopoulos G, Karmpaliotis D, Alaswad K, et al. Application and out-
comes of a hybrid approach to chronic total occlusion percutaneous 
coronary intervention in a contemporary multicenter US registry. Int J 
Cardiol. 2015;198:222-228.
11. Karacsonyi J, Karmpaliotis D, Alaswad K, et al. Prevalence, indications 
and management of balloon uncrossable chronic total occlusions: in-
sights from a contemporary multicenter US registry. Catheter Cardio-
vasc Interv. 2017;90:12-20. Epub 2016 Sep 21.
12. Ambrosini V, Sorropago G, Laurenzano E, et al. Early outcome of high 
energy Laser (Excimer) facilitated coronary angioplasty ON hARD and 
complex calcified and balloOn-resistant coronary lesions: LEONARDO 
study. Cardiovasc Revasc Med. 2015;16:141-146.
13. Latib A, Takagi K, Chizzola G, et al. Excimer laser lesion modification to 
expand non-dilatable stents: the ELLEMENT registry. Cardiovasc Revasc 
Med. 2014;15:8-12.
14. Karacsonyi J, Danek BA, Karatasakis A, Ungi I, Banerjee S, Brilakis ES. Laser 
coronary atherectomy during contrast injection for treating an underex-
panded stent. JACC Cardiovasc Interv. 2016;9:e147-e148. Epub 2016 Jul 13.
15. Ashikaga T, Yoshikawa S, Isobe M. The effectiveness of excimer laser 
coronary atherectomy with contrast medium for underexpanded stent: 
the findings of optical frequency domain imaging. Catheter Cardiovasc 
Interv. 2015;86:946-949.
16. Ambrosini V, Golino L, Niccoli G, et al. The combined use of drug-eluting 
balloon and excimer laser for coronary artery restenosis in-stent treat-
ment: the DERIST study. Cardiovasc Revasc Med. 2017;18:165-168. Epub 
2016 Dec 21.
17. Giri S, Ito S, Lansky AJ, et al. Clinical and angiographic outcome in the 
laser angioplasty for restenotic stents (LARS) multicenter registry. Cath-
eter Cardiovasc Interv. 2001;52:24-34.
18. Nishino M, Mori N, Takiuchi S, et al. Indications and outcomes of excimer 
laser coronary atherectomy: efficacy and safety for thrombotic lesions – 
the ULTRAMAN registry. J Cardiol. 2017;69:314-319.
19. Topaz O, Minisi AJ, Bernardo NL, et al. Alterations of platelet aggregation 
kinetics with ultraviolet laser emission: the “stunned platelet” phenome-
non. Thromb Haemost. 2001;86:1087-1093.
20. Dorr M, Vogelgesang D, Hummel A, et al. Excimer laser thrombus elim-
ination for prevention of distal embolization and no-reflow in patients 
with acute ST elevation myocardial infarction: results from the random-
ized LaserAMI study. Int J Cardiol. 2007;116:20-26.
21. Topaz O, Ebersole D, Das T, et al. Excimer laser angioplasty in acute 
myocardial infarction (the CARMEL multicenter trial). Am J Cardiol. 
2004;93:694-701.
22. Brilakis ES, Lee M, Mehilli J, et al. Saphenous vein graft interventions. Curr 
Treat Options Cardiovasc Med. 2014;16:301.
23. Ebersole DG. Excimer laser for revascularisation of saphenous vein 
grafts. Lasers Med Sci. 2001;16:78-83.
24. Brilakis ES, ed. Manual of Chronic Total Occlusion Interventions. A Step-
By-Step Approach. 2013. Waltham, MA: Elsevier.
25. Kadohira T, Schwarcz AI, De Gregorio J. Successful retrieval of an en-
trapped guide wire between a deployed coronary stent and severely 
calcified vessel wall using excimer laser coronary atherectomy. Catheter 
Cardiovasc Interv. 2015;85:E39-E42.
From the 1VA North Texas Health Care System and UT Southwestern Medical Cen-
ter, Dallas, Texas; 2Division of Invasive Cardiology, Second Department of Internal 
Medicine and Cardiology Center, University of Szeged, Szeged, Hungary; 3VA East-
ern Colorado Health Care System and University of Colorado, Denver, Colorado; 
4Southern Arizona VA Health Care System, Tucson, Arizona; and 5Minneapolis 
Heart Institute, Minneapolis, Minnesota. 
Funding: This was an investigator-initiated study funded by The Spectranetics 
Corporation. 
Disclosure: The authors have completed and returned the ICMJE Form for Disclo-
sure of Potential Conflicts of Interest. Dr Armstrong reports consulting income 
from Spectranetics, Abbott Vascular, Boston Scientific, Medtronic, and CSI. Dr 
Truong reports an institutional research grant subaward from Spectranetics. Dr 
Alame reports the NIH T35 NHLBI Summer Research Training grant. Dr Tsuda 
reports an institutional grant from Spectranetics. Dr Banerjee reports research 
grants from Gilead and the Medicines Company; consultant/speaker honoraria 
from Covidien and Medtronic; ownership in MDCare Global (spouse); intellectual 
property in HygeiaTel. Dr Brilakis reports consulting/speaker honoraria from Ab-
bott Vascular, Acist, Amgen, Asahi Intecc, CSI, Elsevier, GE Healthcare, Medicure, 
and Nitiloop; he serves on the Board of Directors for the Cardiovascular Inno-
vations Foundation and the Board of Trustees of the Society of Cardiovascular 
Angiography and Interventions; spouse is an employee of Medtronic. Dr Rangan 
reports institutional research grants from Spectranetics and InfraRedX. The re-
maining authors report no conflicts of interest regarding the content herein.
Manuscript submitted December 3, 2017 and accepted December 11, 2017.
Address for correspondence: Bavana V. Rangan, BDS, MPH, Dallas VA Medical Center, 




















Contemporary Laser Use DUring pCi KaraCsonyi, et aL.
202 The JourNal of INVasIVe CardIology®
Supplemental Appendix S1. Study details.
A. Participating Centers
Denver VA Medical Center, Denver, Colorado
Southern Arizona VA Health Care System, Tucson, Arizona
VA North Texas Healthcare System, Dallas, Texas
B. Electronic Data Capture Tools
Study data were collected and managed using Research Electronic Data Capture (REDCap) electronic data capture tools 
managed by Veterans Affairs Information Resource Center (VIReC).1 REDCap is a secure, web-based application designed 
to support data capture for research studies, providing (1) an intuitive interface for validated data entry, (2) audit trails for 
tracking data manipulation and export procedures, (3) automated export procedures for seamless data downloads to common 
statistical packages, and (4) procedures for importing data from external sources.
C. Definitions
ELCA-assisted PCI was defined as coronary lesions treated with excimer laser atherectomy. 
Calcification was assessed by angiography as mild (spots), moderate (involving ≤50% of the reference lesion diameter), and 
severe (involving >50% of the reference lesion diameter). 
Moderate proximal vessel tortuosity was defined as the presence of at least 2 bends >70° or 1 bend >90°, and severe tortuosi-
ty as 2 bends >90° or 1 bend >120° in the target vessel. 
Technical success was defined as successful lesion revascularization with achievement of <30% residual diameter stenosis 
within the treated segment and restoration of Thrombolysis In Myocardial Infarction (TIMI) grade 3 antegrade flow. 
Laser success was defined as technical success achieved by laser atherectomy. 
Procedural success was defined as achievement of technical success with no in-hospital major adverse cardiac events (MACE). 
In-hospital MACE included any of the following adverse events prior to hospital discharge: death, myocardial infarction, urgent 
repeat target-vessel revascularization with either PCI or coronary artery bypass graft surgery, tamponade requiring either 
pericardiocentesis or surgery, and stroke. 
Myocardial infarction was defined using the Third Universal Definition of Myocardial Infarction.2 
The following laser catheters were used at the discretion of the operator: 0.9 mm, 1.4 mm or 1.7 mm rapid-exchange excimer 
laser catheter or 0.9 mm over-the-wire catheter. 
1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) - a metadata-driven methodology and 
workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377-381.
2. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation. 2012;126:2020-2035.
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